Full-Time

Strategic Accounts Senior Director

New Business Development

Posted on 5/9/2026

Covetrus

Covetrus

1,001-5,000 employees

Global animal-health distributor and veterinary software

Compensation Overview

$155.1k - $221.5k/yr

+ Variable Incentive

Chicago, IL, USA + 3 more

More locations: Tallahassee, FL, USA | Albany, NY, USA | St Paul, MN, USA

In Person

Category
Business & Strategy (1)
Required Skills
Forecasting
Salesforce
Requirements
  • 12+ years of enterprise sales, strategic account management, or business development experience, with a strong track record of C-suite engagement and large, complex deal execution.
  • Deep understanding of veterinary or healthcare industries, including distribution, technology platforms (PIMS), pharmacy/compounding, and consolidator dynamics.
  • Demonstrated success negotiating multimillion-dollar agreements across multiple stakeholders.
  • Experience leading direct reports and influencing large cross-functional teams.
  • Strong financial acumen with P&L ownership, ROI modeling, and enterprise forecasting experience.
  • Exceptional executive presence, communication, and storytelling ability.
  • Advanced CRM proficiency (Salesforce.com preferred) and familiarity with modern sales methodologies.
Responsibilities
  • Serve as the primary executive-level relationship owner for the largest veterinary consolidators and corporate groups.
  • Develop and deliver compelling enterprise business cases that align Covetrus solutions to customer growth, efficiency, and financial objectives.
  • Lead negotiations for multi-year, multimillion-dollar contracts involving complex stakeholder groups (legal, finance, supply chain, operations).
  • Push organizational innovation by advocating for the right offers, bundled solutions, and deal structures that differentiate Covetrus in the market.
  • Conduct quarterly executive business reviews (QBRs) with client leadership to assess value delivered and identify expansion opportunities.
  • Define and execute long-term account strategies that expand share of wallet across distribution, technology, and pharmacy/compounding solutions.
  • Monitor competitive dynamics, market trends, and customer economics to adjust strategies proactively.
  • Partner with Marketing, Product, and Category Management to influence solution design and GTM priorities based on enterprise customer needs.
  • Direct and mentor a team of Strategic Account Managers responsible for daily account operations, procurement engagement, and regional execution.
  • Set performance expectations, KPIs, and development plans for direct reports, ensuring alignment with enterprise-level objectives.
  • Provide executive sponsorship and escalation support to resolve issues, ensure contract compliance, and maintain customer satisfaction.
  • Build ROI models, pricing strategies, and financial forecasts to support enterprise-level deals.
  • Partner with Finance and Commercial Operations to ensure accuracy in forecasting, profitability analysis, and performance tracking.
  • Maintain strong CRM hygiene and pipeline management discipline to drive forecast predictability.
  • Distill complex solutions into clear, compelling executive narratives.
  • Influence both internal leadership and external C-suite stakeholders to drive consensus in sensitive, high-stakes negotiations.
  • Represent Covetrus at industry events, conferences, and customer forums as a thought leader.
Desired Qualifications
  • MBA or advanced degree in Business, Sales, or related field.
  • Experience shaping enterprise GTM strategies that blend product-led and sales-led growth.
  • Training in value-based selling, solution selling, or strategic negotiation frameworks (e.g., Miller Heiman, Challenger)

Covetrus is a global animal-health technology and services company that combines the distribution of veterinary products with cloud-based software and services. Its platform integrates practice management, prescription management, and client communications with an online pharmacy and home delivery to pet owners. It differentiates itself by linking physical distribution with digital infrastructure and analytics in a single ecosystem, helping practices run operations end-to-end and keep revenue within Covetrus. Its goal is to streamline veterinary workflows, improve client engagement, and support practice growth on a global scale.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Portland, Maine

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquires MWI Animal Health for $1.25B, consolidating U.S. distributors and enhancing logistics.
  • Refinances $3.5B debt with Blue Owl to fund MWI acquisition and growth.
  • Merges with Conduent in $3.5B all-stock deal, adding healthcare outsourcing capabilities.

What critics are saying

  • FTC blocks Covetrus-MWI merger, reducing competition to two distributors.
  • Independent vets boycott over vertical integration, pricing leverage, and vendor lock-in.
  • Securitization caps in Blue Owl refinancing restrict off-balance-sheet financing options.

What makes Covetrus unique

  • Covetrus integrates veterinary distribution, practice management software, and prescription services.
  • Founded by Benjamin Shaw from Vets First Choice and David Shaw of IDEXX Laboratories.
  • Covetrus Platform combines AI workflow automation with VetSuite network for practices.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Covetrus who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Employee Discounts

Company Social Events

Company News

9fin
Apr 8th, 2026
Direct lenders look to cap securitizations post First Brands.

Direct lenders look to cap securitizations post First Brands. Private credit lenders are increasingly negotiating securitization limits into credit agreements to guard against the kind of runaway off-balance sheet financings that led to the bankruptcies of First Brands and Tricolor, according to 9fin sources. One such provision recently cleared the market in the $3.5bn refinancing that direct lenders arranged for veterinary technology platform Covetrus, sources said. When the company and its sponsor, CD&R, turned to private credit lenders led by Blue Owl to refinance its syndicated debt and upsize its facility to fund its acquisition of MWI Health, lenders took the opportunity to introduce protections that cap the amount a business can raise through accounts receivable factoring or securitization, sources said. Ultimately, such a clause would limit a borrower's ability to raise some forms off-balance-sheet financing that went largely undetected and led to the demise of companies like First Brands. Blue Owl and Covetrus declined to comment. CD&R did not respond to requests for comment. Covetrus is among a growing number of private credit-backed deals with these types of guardrails, sources told 9fin, noting that lenders in the broadly syndicated loan market are also pushing to include similar provisions in their credit documents. Read all our public content for free. You may unsubscribe from these communications at any time. Discover more insights. Use the previous and next buttons or keyboard arrows to navigate between slides.

VINnews
Feb 20th, 2026
Covetrus and MWI Animal Health plan to merge

Covetrus and MWI Animal Health plan to merge. Covetrus and MWI Animal Health plan to merge Deal would mark a significant consolidation of distributors of veterinary products Published: February 19, 2026 By Lisa Wogan Series See related stories " Covetrus_HQ VIN News Service 2023 photo Covetrus is headquartered in Portland, Maine. Covetrus has agreed to acquire MWI Animal Health in a move that will reduce to two the number of nationwide distributors of veterinary pharmaceuticals, equipment and supplies in the United States. MWI is being sold by its parent company, Cencora, for $1.25 billion in cash, plus shares that will give it a 34.3% stake in the combined company. In an announcement Wednesday, Covetrus said merging the companies will result in expanded and improved services that benefit veterinarians and their patients by making care more affordable and accessible. But some of their customers immediately raised concerns that the merger may have negative consequences because of reduced competition. Covetrus is an international company that distributes products and sells practice management software and online pharmacy services to veterinarians. The Portland, Maine-based company was created from a merger of Henry Schein Animal Health and Vets First Choice in early 2019. After a three-year stint as a public company, Covetrus was taken private by a pair of private equity firms in 2022. Based in Boise, Idaho, MWI was founded more than 50 years ago by a veterinarian to serve nearby colleagues and grew into a major veterinary distributor. It was purchased for $2.5 billion in 2015 by an international pharmaceutical company, AmerisourceBergen Corp, now named Cencora. Covetrus CEO Ben Wolin said the merger would allow the combined company to improve its logistics capabilities, "create savings" and invest in innovation. "This combination is about making animal healthcare more affordable and accessible, and we remain committed to driving innovation across the industry," he said in a press release. Cencora indicated that it would prefer to focus on other parts of its business, which include drug distribution and research in the human health care realm. "This transaction positions MWI for success with a partner strategically focused on and dedicated to animal health, while allowing Cencora to further invest in our key growth priorities," Cencora CEO Bob Mauch said. The only other major U.S. veterinary distributor is Patterson Companies. Formerly a public company, Patterson was purchased and taken private last year by Patient Square Capital, a health care investment firm. In brief * Covetrus announced plans to acquire MWI Animal Health. * The merger will reduce to two the number of nationwide distributors of veterinary pharmaceuticals, equipment and supplies. * Covetrus said the deal will make veterinary care more affordable and accessible. * The news immediately drew criticism that the merger would be unhealthy for the veterinary profession. The next largest veterinary distributor is Midwest Veterinary Supply, a family- and employee-owned company in Minnesota. There are also a handful of regional and specialized veterinary distributors. Seventeen years ago, the veterinary distribution landscape was notably different. There were six companies with national reach, according to a tally in 2009 by the executive director of the American Veterinary Distributors Association. At that time, consolidation was well underway; the association had lost 11 distributor members in seven years. To stay viable, the group later recast itself as the United Veterinary Services Association, with a membership encompassing manufacturers, suppliers and nonprofit organizations as well as distributors. Covetrus' move on MWI may draw the attention of the Federal Trade Commission, which reviews mergers and acquisitions that could substantially reduce competition. Cencora has said it expects the transaction to close after Sept. 30. The announcement does not address the future status of MWI employees. Immediate concerns voiced On the day of the announcement, James Rericha published an open letter on LinkedIn urging Cencora to spin off MWI as a standalone company rather than sell it to Covetrus. Rericha and his wife, Dr. Katie Rericha, own eight veterinary clinics in Missouri. He also urged federal regulators to listen to veterinarians' concerns when they evaluate the deal. Rericha told the VIN News Service that he is a customer of both MWI and Covetrus. He believes MWI can be a strong company on its own, to the benefit of the profession. In his letter, he describes the merger as harmful to practices like his. Merging MWI's "distribution muscle" with Covetrus' technology and services platform "creates a vertically integrated giant that controls the supply chain, the software, and the data," he writes. "For independent practices, that concentration of power raises real questions about pricing leverage, vendor lock-in, and whether the combined entity will prioritize its own platform over open interoperability." Open interoperability is the ability of systems, devices and software from different vendors to work together and easily exchange data. In contrast to a merged company, Rericha writes, "an independent MWI would have every incentive to earn customer loyalty through better service, open integrations, and competitive pricing - because it would have to." Responding to Rericha's letter, Wes Hentges, founder of Missouri-based ProPartners, a business and financial management company for veterinary clinic owners, agreed that the merger is worrisome. "On the surface, the companies say it will help vets with access and efficiency," he wrote, "but in reality, it reduces competition and puts more pricing and platform power into fewer hands. When distribution, software, and services are wrapped together, independent clinics lose leverage and choice." Hentges compared the concerns to those raised during the proposed merger of the grocery giants Kroger and Albertsons. Federal regulators blocked the merger on the basis that it would reduce competition and likely increase prices. "That same dynamic, fewer big players with more control, can hurt customers even if the companies say otherwise," Hentges wrote. A Covetrus spokesperson declined today to comment on the concerns. VIN News Service commentaries are opinion pieces presenting insights, personal experiences and/or perspectives on topical issues by members of the veterinary community. To submit a commentary for consideration, email [email protected]. Information and opinions expressed in letters to the editor are those of the author and are independent of the VIN News Service. Letters may be edited for style. We do not verify their content for accuracy.

AD HOC NEWS Portal Aktiengesellschaft
Feb 19th, 2026
Conduent agrees $3.5B all-stock merger with TPG-backed Covetrus

Conduent has agreed to an all-stock merger with Covetrus, a TPG portfolio company, in a deal valuing the combined entity at approximately $3.5 billion. TPG will emerge as the controlling shareholder following the transaction's completion. The business process outsourcing company's shares surged on the announcement as investors repriced the stock around the transaction value and anticipated cost synergies. The merger combines Conduent's government, transportation and healthcare services with Covetrus's animal health technology platform. For existing Conduent shareholders, the deal offers stock in the combined company rather than cash consideration. The transaction requires shareholder and regulatory approvals before closing. Wall Street analysts view the merger as strategically positive but emphasise the need for clarity on synergy timing and leverage profile.

e-MAG
May 5th, 2025
The Evolution of AI in Animal Health for Veterinarians

Covetrus, in collaboration with Zoetis Diagnostics, is creating more efficient, integrated veterinary systems, combining cutting-edge testing with practice management tools.

Techseriesinsight
Jan 27th, 2025
Covetrus Announces AI-Powered Workflow Automation and Treatment Board Capabilities Enhancing the Covetrus Platform

Covetrus(R), the first tech-enabled veterinary practice improvement company, today announced at the VMX 2025 conference (booth #2104) its AI-powered workflow automation and treatment board capabilities within Covetrus Pulse(TM), now an integral part of the newly advanced Covetrus Platform(TM).